{"denoms":[{"counts":[{"groupId":"BG000","value":"92"},{"groupId":"BG001","value":"85"},{"groupId":"BG002","value":"177"}],"units":"Participants"}],"groups":[{"description":"400 mg sorafenib by mouth twice a day for 28-day cycle. Continue up to 5 years in the absence of disease progression or unacceptable toxicity.","id":"BG000","title":"Sorafenib Alone"},{"description":"27.5 Gy to 50 Gy stereotactic body radiation therapy (SBRT) in 5 fractions 24-72 hours apart over 5-15 days followed within 1-5 days by one cycle of 200 mg sorafenib by mouth twice a day. Starting with second cycle, if tolerable, increase to 400 mg sorafenib by mouth twice a day. Continue up to 5 years in the absence of disease progression or unacceptable toxicity.","id":"BG001","title":"SBRT Followed by Sorafenib"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"27","upperLimit":"84","value":"67"},{"groupId":"BG001","lowerLimit":"49","upperLimit":"83","value":"66"},{"groupId":"BG002","lowerLimit":"27","upperLimit":"84","value":"66"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"4"}],"title":"≤ 49 years"},{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"35"}],"title":"50 - 59 years"},{"measurements":[{"groupId":"BG000","value":"39"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"81"}],"title":"60 - 69 years"},{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"44"}],"title":"70 - 79 years"},{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"13"}],"title":"≥ 80 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"27"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"82"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"150"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"8"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"47"},{"groupId":"BG002","value":"101"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"36"},{"groupId":"BG002","value":"68"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"41"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"8"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"59"},{"groupId":"BG002","value":"117"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"9"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"47"},{"groupId":"BG002","value":"88"}],"title":"0"},{"measurements":[{"groupId":"BG000","value":"44"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"77"}],"title":"1"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"12"}],"title":"2"}]}],"description":"0 - Asymptomatic; 1 - Symptomatic but completely ambulatory; 2 - Symptomatic, \\<50% in bed during the day; 3 - Symptomatic, \\>50% in bed, but not bedbound; 4 - Bedbound; 5 - Death","paramType":"COUNT_OF_PARTICIPANTS","title":"Zubrod performance status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"15"}],"title":"T1"},{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"36"}],"title":"T2"},{"measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"28"}],"title":"T3a"},{"measurements":[{"groupId":"BG000","value":"49"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"87"}],"title":"T3b"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"11"}],"title":"T4"}]}],"description":"Tumor stage per the American Joint Committee on Cancer (AJCC) 7th ed. refers to the size and/or extent of the main tumor. The higher the number after the T, the larger the tumor or the more it has grown into nearby tissues. T's may be further divided to provide more detail, such as T3a and T3b.","paramType":"COUNT_OF_PARTICIPANTS","title":"T Stage","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"89"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"169"}],"title":"N0"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"}],"title":"N1"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"NX"}]}],"description":"Regional lymph nodes staging per American Joint Committee on Cancer (AJCC) 7th ed. refers to the number and/or extent of spread of lymph nodes that contain cancer. The higher the number after the N, the greater the involvement of regional lymph nodes. (N0= no cancer in nearby lymph nodes; NX = cannot be measured.)","paramType":"COUNT_OF_PARTICIPANTS","title":"N Stage","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"88"},{"groupId":"BG001","value":"82"},{"groupId":"BG002","value":"170"}],"title":"M0"},{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"7"}],"title":"M1"}]}],"description":"Metastasis stage per the American Joint Committee on Cancer (AJCC) 7th ed. refers to the spread of the cancer to organs and tissues in other parts of the body. M0 = No distant metastasis; M1 = Distant metastasis; MX = Distant metastasis cannot be assessed.","paramType":"COUNT_OF_PARTICIPANTS","title":"M Stage","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"69"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"133"}],"title":"5 (Grade A)"},{"measurements":[{"groupId":"BG000","value":"23"},{"groupId":"BG001","value":"21"},{"groupId":"BG002","value":"44"}],"title":"6 (Grade A)"}]}],"description":"Child Pugh Classification uses the following to determine liver function: 1) bilirubin levels; 2) albumin levels; 3) how quickly the blood clots (prothrombin time); 4) if there is fluid in the abdomen (ascites); and 5) if there is encephalopathy (liver disease has affected brain function). Each one of the previous is given a score: 5 (Grade A) and 6 (Grade A) mean the liver is working normally.","paramType":"COUNT_OF_PARTICIPANTS","title":"Child Pugh Score","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"32"}],"title":"Intermediate (B)"},{"measurements":[{"groupId":"BG000","value":"77"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"145"}],"title":"Advanced (C)"}]}],"description":"Barcelona Clinic Liver Cancer (BCLC) staging system helps doctors determine the best treatment using 1) the number and size of tumors in the liver, 2) general health status or Zubrod performance status, and 3) liver function using Child-Pugh score. Intermediate(B): many tumors in liver, but overall status is good (Zubrod=0) and liver function is good with Child Pugh A or B. Advanced(C): cancer has spread, Zubrod=1 or 2, but liver function is still good with Child Pugh A or B.","paramType":"COUNT_OF_PARTICIPANTS","title":"BCLC Stage","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"40"},{"groupId":"BG002","value":"80"}],"title":"<10%"},{"measurements":[{"groupId":"BG000","value":"42"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"81"}],"title":"10-40%"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"16"}],"title":">40%"}]}],"description":"The ratio of hepatocellular volume to the liver volume (as a percent).","paramType":"COUNT_OF_PARTICIPANTS","title":"Hepatocellular carcinoma (HCC) tumor volume / liver volume","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"33"}],"title":"Hepatitis B or B and C"},{"measurements":[{"groupId":"BG000","value":"38"},{"groupId":"BG001","value":"35"},{"groupId":"BG002","value":"73"}],"title":"Hepatitis C"},{"measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"34"},{"groupId":"BG002","value":"71"}],"title":"Other"}]}],"description":"Hepatitis is a type of liver disease that causes inflammation of the liver, which can be caused by alcohol, injury, autoimmune response, or a reaction to bacteria or virus. Hepatitis B may result in chronic liver disease or liver cancer. Hepatitis C may result in cirrhosis or liver cancer. Other (Hepatitis A) mostly likely will result in no liver damage.","paramType":"COUNT_OF_PARTICIPANTS","title":"Hepatitis Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"66"},{"groupId":"BG001","value":"62"},{"groupId":"BG002","value":"128"}],"title":"Yes"},{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"49"}],"title":"No"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Enhancing vascular thrombosis","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"90"},{"groupId":"BG001","value":"85"},{"groupId":"BG002","value":"175"}],"title":"North America"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}],"title":"Other"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"}],"populationDescription":"Eligible participants"}